SCYNEXIS Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
30,461.00
4,234.00
32,623.00
29,989.00
25,060.00
12,468
Depreciation, Depletion & Amortization
1,329.00
1,238.00
447.00
26.00
41.00
53
Other Funds
21,302.00
7,087.00
3,574.00
3,643.00
568.00
9,507
Funds from Operations
7,830.00
10,083.00
28,602.00
26,320.00
25,587.00
21,922
Changes in Working Capital
3,523.00
611.00
4,057.00
3,033.00
1,031.00
6,401
Net Operating Cash Flow
4,307.00
9,472.00
24,545.00
29,353.00
24,556.00
28,323
Capital Expenditures
431.00
704.00
589.00
27.00
2.00
Sale of Fixed Assets & Businesses
988.00
-
2,549.00
500.00
-
Purchase/Sale of Investments
-
-
374.00
22,945.00
9,618.00
Net Investing Cash Flow
557.00
488.00
1,586.00
22,472.00
9,620.00
Issuance/Reduction of Debt, Net
899.00
15,000.00
-
14,396.00
-
Net Financing Cash Flow
2,767.00
40,801.00
37,701.00
40,496.00
9,989.00
Net Change in Cash
983.00
30,841.00
14,742.00
11,329.00
24,187.00
Free Cash Flow
4,738.00
10,176.00
25,134.00
29,380.00
24,558.00
Other Sources
-
216.00
-
-
-
Change in Capital Stock
1,868.00
55,801.00
37,701.00
26,100.00
9,989.00

About SCYNEXIS

View Profile
Address
1 Evertrust Plaza
Jersey City New Jersey 07302
United States
Employees -
Website http://www.scynexis.com
Updated 07/08/2019
SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.